Radiotherapy & Oncology
Volume 94, Issue 3 , Pages 280-285 , March 2010

Current technological clinical practice in breast radiotherapy; results of a survey in EORTC-Radiation Oncology Group affiliated institutions

  • Hans Paul van der Laan

      Affiliations

    • Department of Radiation Oncology, University Medical Center Groningen/University of Groningen, Groningen, The Netherlands
    • Corresponding Author InformationCorresponding author. Address: Department of Radiation Oncology, University Medical Center Groningen, PO Box 30001, 9700 RB Groningen, The Netherlands.
    • ,
  • Coen W. Hurkmans

      Affiliations

    • Department of Radiation Oncology, Catharina Hospital, Eindhoven, The Netherlands
    • ,
  • Abraham Kuten

      Affiliations

    • Division of Oncology, Rambam Health Care Campus, Faculty of Medicine, Technion, Haifa, Israel
    • ,
  • Helen A. Westenberg

      Affiliations

    • Institute for Radiation Oncology Arnhem, Arnhem, The Netherlands
    • ,
  • On behalf of the EORTC-ROG Breast Working Party

Received 21 September 2009 ,Revised 9 December 2009 ,Accepted 29 December 2009.

References 

  1. Agren Cronqvist AK, Kallman P, Turesson I, et al. Volume and heterogeneity dependence of the dose–response relationship for head and neck tumours. Acta Oncol. 1995;34:851–860
  2. Poortmans PM, Venselaar JL, Struikmans H, et al. The potential impact of treatment variations on the results of radiotherapy of the internal mammary lymph node chain: a quality-assurance report on the dummy run of EORTC Phase III randomized trial 22922/10925 in Stage I–III breast cancer. Int J Radiat Oncol Biol Phys. 2001;49:1399–1408
  3. Peters L, O’Sullivan B, Girald J, et al. Critical impact of radiotherapy protocol compliance and plan quality in treatment of advanced head and neck cancer (Abstr.). In: Second ICHNO conference abstract book; 2009. p. s6.
  4. Delaney G, Blakey D, Drummond R, et al. Breast radiotherapy: an Australasian survey of current treatment techniques. Australas Radiol. 2001;45:170–178
  5. Winfield E, Deighton A, Venables K, et al. Survey of UK breast radiotherapy techniques: background prior to the introduction of the quality assurance programme for the START (standardisation of radiotherapy) trial in breast cancer. Clin Oncol (R Coll Radiol). 2002;14:267–271
  6. Jalali R, Singh S, Budrukkar A. Techniques of tumour bed boost irradiation in breast conserving therapy: current evidence and suggested guidelines. Acta Oncol. 2007;46:879–892
  7. Vu TT, Pignol JP, Rakovitch E, et al. Variability in radiation oncologists’ opinion on the indication of a bolus in post-mastectomy radiotherapy: an international survey. Clin Oncol (R Coll Radiol). 2007;19:115–119
  8. Thomsen MS, Berg M, Nielsen HM, et al. Post-mastectomy radiotherapy in Denmark: from 2D to 3D treatment planning guidelines of The Danish Breast Cancer Cooperative Group. Acta Oncol. 2008;47:654–661
  9. Morgia M, Lamoury G, Morgan G. Survey of radiotherapy planning and treatment of the supraclavicular fossa in breast cancer. J Med Imaging Radiat Oncol. 2009;53:207–211
  10. Drummond R, Power A, Evans A, et al. Changes in practice of breast cancer radiotherapy 1998–2002: an Australasian survey. Australas Radiol. 2005;49:44–52
  11. Hurkmans CW, Meijer GJ, van Vliet-Vroegindeweij C, et al. High-dose simultaneously integrated breast boost using intensity-modulated radiotherapy and inverse optimization. Int J Radiat Oncol Biol Phys. 2006;66:923–930
  12. van der Laan HP, Dolsma WV, Maduro JH, et al. Three-dimensional conformal simultaneously integrated boost technique for breast-conserving radiotherapy. Int J Radiat Oncol Biol Phys. 2007;68:1018–1023
  13. Hurkmans CW, Borger JH, Bos LJ, et al. Cardiac and lung complication probabilities after breast cancer irradiation. Radiother Oncol. 2000;55:145–151
  14. Bentzen SM, Agrawal RK, Aird EG, et al. The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet. 2008;371:1098–1107
  15. Bentzen SM, Agrawal RK, Aird EG, et al. The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncol. 2008;9:331–341
  16. Whelan T, MacKenzie R, Julian J, et al. Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node-negative breast cancer. J Natl Cancer Inst. 2002;94:1143–1150
  17. Whelan TJ, Pignol J, Julian J, et al. Long-term results of a randomized trial of accelerated hypofractionated whole breast irradiation following breast conserving surgery in women with node-negative breast cancer (Abstract). Int J Radiat Oncol Biol Phys. 2008;18:S28
  18. Owen JR, Ashton A, Bliss JM, et al. Effect of radiotherapy fraction size on tumour control in patients with early-stage breast cancer after local tumour excision: long-term results of a randomised trial. Lancet Oncol. 2006;7:467–471
  19. Joiner MC, van der Kogel AJ. The linear-quadratic approach to fractionation and calculation of isoeffect relationships. In:  Steel GG editors. Basic clinical radiobiology. 2nd ed.. London: Arnold; 1997;
  20. Yang TI, Elkhuizen PH, Minkema D, et al. Clinical factors associated with seroma volume reduction in breast-conserving therapy for early-stage breast cancer: a multi-institutional analysis. Int J Radiat Oncol Biol Phys. 2009;
  21. McDonald MW, Godette KD, Whitaker DJ, et al. Three-year outcomes of breast intensity-modulated radiation therapy with simultaneous integrated boost. Int J Radiat Oncol Biol Phys. 2009;
  22. Veness MJ, Delaney G. Variations in breast tangent radiotherapy: a survey of practice in New South Wales and the Australian Capital Territory. Australas Radiol. 1999;43:334–338
  23. Pignol JP, Olivotto I, Rakovitch E, et al. A multicenter randomized trial of breast intensity-modulated radiation therapy to reduce acute radiation dermatitis. J Clin Oncol. 2008;26:2085–2092
  24. Donovan E, Bleakley N, Denholm E, et al. Randomised trial of standard 2D radiotherapy (RT) versus intensity modulated radiotherapy (IMRT) in patients prescribed breast radiotherapy. Radiother Oncol. 2007;82:254–264
  25. Harsolia A, Kestin L, Grills I, et al. Intensity-modulated radiotherapy results in significant decrease in clinical toxicities compared with conventional wedge-based breast radiotherapy. Int J Radiat Oncol Biol Phys. 2007;68:1375–1380
  26. Vicini F, Beitsch PD, Quiet CA, et al. Three-year analysis of treatment efficacy, cosmesis, and toxicity by the American Society of Breast Surgeons MammoSite Breast Brachytherapy Registry Trial in patients treated with accelerated partial breast irradiation (APBI). Cancer. 2008;112:758–766
  27. Bartelink H, Horiot JC, Poortmans PM, et al. Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10-year results of the randomized boost versus no boost EORTC 22881-10882 trial. J Clin Oncol. 2007;25:3259–3265
  28. Benda RK, Yasuda G, Sethi A, et al. Breast boost: are we missing the target?. Cancer. 2003;97:905–909
  29. Poortmans P, Bartelink H, Horiot JC, et al. The influence of the boost technique on local control in breast conserving treatment in the EORTC ‘boost versus no boost’ randomised trial. Radiother Oncol. 2004;72:25–33
  30. Hurkmans CW, Borger JH, Pieters BR, et al. Variability in target volume delineation on CT scans of the breast. Int J Radiat Oncol Biol Phys. 2001;50:1366–1372
  31. Holland R, Veling SH, Mravunac M, et al. Histologic multifocality of Tis, T1-2 breast carcinomas. Implications for clinical trials of breast-conserving surgery. Cancer. 1985;56:979–990
  32. Faverly DR, Hendriks JH, Holland R. Breast carcinomas of limited extent: frequency, radiologic–pathologic characteristics, and surgical margin requirements. Cancer. 2001;91:647–659
  33. Stroom J, Schlief A, Alderliesten T, et al. Using histopathology breast cancer data to reduce clinical target volume margins at radiotherapy. Int J Radiat Oncol Biol Phys. 2009;74:898–905
  34. Jones HA, Antonini N, Hart AA, et al. Impact of pathological characteristics on local relapse after breast-conserving therapy: a subgroup analysis of the EORTC boost versus no boost trial. J Clin Oncol. 2009;27:4939–4947
  35. van der Laan HP, Dolsma WV, Maduro JH, et al. Dosimetric consequences of the shift towards computed tomography guided target definition, planning for breast conserving radiotherapy. Radiat Oncol. 2008;3:6
  36. Uwini SA, Antonini N, Poortmans PM, et al. The influence of the use of CT-planning on the irradiated boost volume in breast conserving treatment. Radiother Oncol. 2009;93:87–93
  37. Hurkmans C, Admiraal M, van der Sangen M, et al. Significance of breast boost volume changes during radiotherapy in relation to current clinical interobserver variations. Radiother Oncol. 2009;90:60–65
  38. Hooning MJ, Botma A, Aleman BM, et al. Long-term risk of cardiovascular disease in 10-year survivors of breast cancer. J Natl Cancer Inst. 2007;99:365–375
  39. van der Laan HP, Dolsma WV, Van’t Veld AA, et al. Comparison of normal tissue dose with three-dimensional conformal techniques for breast cancer irradiation including the internal mammary nodes. Int J Radiat Oncol Biol Phys. 2005;63:1522–1530
  40. Chino JP. Marks LB Prone positioning causes the heart to be displaced anteriorly within the thorax: implications for breast cancer treatment. Int J Radiat Oncol Biol Phys. 2008;70:916–920
  41. Giro C, Berger B, Bolke E, et al. High rate of severe radiation dermatitis during radiation therapy with concurrent cetuximab in head and neck cancer: results of a survey in EORTC institutes. Radiother Oncol. 2009;90:166–171

PII: S0167-8140(10)00009-5

doi: 10.1016/j.radonc.2009.12.032

Radiotherapy & Oncology
Volume 94, Issue 3 , Pages 280-285 , March 2010

Article Tools

* Image Usage & Resolution